AUTHORS
Luciano J. Costa, MD, PhD, Guido Lancman2, Jing Christine Ye, M.D., MSc3, Noffar Bar, MD4, Sosana Delimpasi, MD5, Emma Searle, MBChB, PhD6, Raphael Teipel7, Katja Weisel, MD8, Samhita Chakraborty, MD9, Erik Vandendries, MD, PhD10, Palanikumar Ravindran11, Danny V. Jeyaraju, PhD12, Kevin Hsu, PharmD13, Jessica Katz, MD, PhD14, Tim Campbell, MD, PhD15, Colin Godwin, MD16, Nizar Bahlis, MD17
AFFILIATIONS
1 Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, United States
2 Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
3 MD Anderson Cancer Center, Houston, Texas, United States
4 Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, United States
5 Department of Haematology, Evangelismos Hospital, Athens, Greece
6 The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom
7 Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
8 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
9 Oncology Research and Development, Pfizer Inc, New York, NY, United States
10 Oncology Research and Development, Pfizer Inc, Cambridge, MA, United States
11 Bristol Myers Squibb, Princeton, NJ, United States
12 Bristol Myers Squibb, Princeton, NJ, United States
13 Bristol Myers Squibb, Princeton, NJ, United States
14 Bristol Myers Squibb, Princeton, NJ, United States
15 Bristol Myers Squibb, Princeton, NJ, United States
16 Bristol Myers Squibb, Princeton, NJ, United States
17 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
ABSTRACT
Introduction: Mezigdomide (Mezi) is a novel potent cereblon E3 ligase modulator that induces maximal, rapid Ikaros/Aiolos degradation leading to enhanced multiple myeloma-cell death and immune stimulation vs immunomodulatory drugs. When combined with carfilzomib and dexamethasone (Kd), Mezi significantly improved median progression-free survival vs Kd in patients (pts) with RRMM with up to 9 prior lines of therapy (LOTs) in the phase 3 SUCCESSOR-2 trial (Dimopoulos MA, et al. Lancet 2026;408:219–233). In preclinical models, Mezi enhances T-cell function and overall B-cell maturation antigen (BCMA)-targeting T-cell engager (TCE) activity (Paiva B, et al. Blood 2022;140[S1]:7054–7055). Initial clinical data support the feasibility and activity of combining Mezi and the BCMA TCE, elranatamab (Elra) (Byun JM, et al. Blood 2025;146[S1]:5835). As monotherapy, Elra has demonstrated deep (61% overall response rate [ORR]; 35% complete response rate [CRR]) and durable responses in pts with RRMM and a median of 5 prior LOTs (Lesokhin AM, et al. Nat Med 2023;29:2259–2267). Mechanisms of primary resistance and relapse for BCMA TCEs include initial or acquired T-cell dysfunction; these may be addressed by the combination with Mezi. CA057-1040 is a phase 1b/2a multicenter, open-label trial evaluating the safety and preliminary efficacy of Mezi plus Elra. Here, we present initial phase 1 data from the CA057-1040 trial.
Methods: Pts in phase 1 had RRMM and 2–4 prior anti-myeloma LOTs, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. Prior chimeric antigen receptor T cell therapy (CAR T) was allowed if >6 mo prior to enrollment; prior TCE was excluded. Step-up dosing of Elra was administered in cycle 0 (14 days; 12, 32, and 76 mg on day (D) 1, D4, and D8, respectively), then 76 mg every 2 weeks, followed by a protocol-specified transition to every 4-week dosing thereafter. Oral dexamethasone 40 or 20 mg was administered weekly in cycles 1–3. Mezi was administered D1–21 from cycle 1. Mezi dose levels were 0.3 mg, 0.6 mg, and 1 mg. Primary objectives included determining safety/tolerability and recommended phase 2 dose of Mezi plus Elra.
Results: As of the data cutoff (DCO; June 15, 2026), 16 pts were enrolled (median follow-up [mFU] 2.8 mo, range 0.3–6.3) including 7 at 0.3 mg (mFU 4.6 mo, range 2.5–6.3), 8 at 0.6 mg (mFU 2.7 mo, range 0.4–3.1), and 1 at 1 mg (FU 0.3 mo). Median age was 67 years, and 50% were male. Twenty-five percent had high-risk cytogenetics, 13% had International Staging System stage III disease at study entry, and 6% had soft tissue plasmacytomas. Pts had a median of 2 prior LOTs (range 2–4), 100% had triple-class–exposed myeloma, and 56% were triple-class refractory. One (6%) pt had prior BCMA CAR T exposure and 1 (6%) had exposure to both BCMA CAR T and GPRC5D CAR T.
All pts had at ≥1 treatment-emergent adverse event (TEAE) and 69% had at ≥1 grade (G) 3–4 TEAE. The most common TEAEs (in ≥40% of pts) were neutropenia (any G 56%, all G3–4 56%), anemia (44%, all G3–4 25%), cytokine release syndrome (44%, all G1–2), and fatigue (44%, all G1–2). Infections occurred in 38% of pts (6% G3, no G4 or higher). G1 immune effector-cell associated neurotoxicity syndrome (ICANS) occurred in 1 pt; no G2 or higher ICANS was observed. One pt each at 0.3 mg and 0.6 mg experienced a dose-limiting toxicity of G4 neutropenia.
Thirteen pts were evaluable for response after at ≥1 combination cycle (n=7, Mezi 0.3 mg; n=6, 0.6 mg). At Mezi 0.3 mg, ORR was 100%, including 86% CRR and 100% very good partial response or better rate (≥VGPRR); at 0.6 mg, ORR was 100%, CRR 17%, and ≥VGPRR 67%. All pts were still on treatment and all responses were ongoing at DCO. Responses were observed in 2 pts with prior CAR T exposure and 2 pts with increased involved light chain during cycle 0 (Elra alone).
Immunophenotyping of paired bone marrow and peripheral blood samples demonstrated that Mezi plus Elra enhanced T- and NK-cell activation and increased their effector lineages, most notably CD8+ effector memory cells. This pharmacodynamic activity was greater at 0.6 mg vs 0.3 mg Mezi.
Conclusions: Mezi plus Elra showed manageable toxicity and encouraging response rates with limited follow-up in a majority triple-class–refractory population. Initial translational findings provide a mechanistic rationale for the observed clinical activity. Phase 1 dose escalation is ongoing; updated data will be presented.
DISCLOSURES
Luciano J. Costa, MD, PhD: Sanofi - Honoraria; Amgen - Honoraria; Adaptive Biotechnologies - Honoraria; Caribou - Honoraria; BeOne - Honoraria; Regeneron - Honoraria; Pfizer - Honoraria; Genentech/Roche - Honoraria; Bristol-Myers-Squibb - Honoraria; AstraZeneca - Honoraria; Moderna - Honoraria; Johnson & Johnson - Honoraria; Pfizer - Research Funding; Gracell - Research Funding; Moderna - Research Funding; Bristol-Myers-Squibb - Research Funding; Johnson & Johnson - Research Funding; Caribou - Research Funding; AstraZeneca - Research Funding; AbbVie - Research Funding; Amgen - Research Funding; Genentech/Roche - Research Funding; AbbVie - Consultancy (Includes expert testimony); Bristol-Myers-Squibb - Consultancy (Includes expert testimony); Moderna - Consultancy (Includes expert testimony); Caribou - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Genentech/Roche - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony)